Bristol-Myers Squibb Discusses the Sale of Diabetes Business to AstraZeneca and 2014 EPS Guidance Conference Call Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other Dec 19 Calls
Today's Calls
Call Details
Bristol-Myers Squibb Discusses the Sale of Diabetes Business to AstraZeneca and 2014 EPS Guidance Conference Call
Scheduled to start Thu, Dec 19, 2013, 8:30 am Eastern

-- this event is ongoing now--
Listen to the ongoing live event audio stream

About Bristol-Myers Squibb Co (NYSE:BMY)Other Calls 
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company’s products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.


More Info: Quote | Chart | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings
About AstraZeneca PLC (LSE:AZN.L)
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics; and a strategic collaboration with FibroGen, Inc. to develop and commercialize FG-4592, a compound for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.


More Info: Quote | Chart | News | Profile | Reports | Research


Copyright © 2014 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2014 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.